Co-beneldopa - Parkinson's disease
You are here : Home > Formulary Search > Co-beneldopa - Parkinson's disease
I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.
Documentation
Guidelines (National)
PAD Profile
ChemicalSubstance :
Co-beneldopa
Indication :
Parkinson's disease
Group Name :
Keywords :
PD, levodopa, dopamine
Brand Names Include :
Madopar
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
1
Other Indications
Below are listed other indications that Co-beneldopa is used to treat.
Other Drugs
Below are listed other drugs that are used to treat Parkinson's disease.
- Amantadine hydrochloride
- Apomorphine hydrochloride
- Bromocriptine
- Cabergoline
- Clonazepam
- Co-careldopa
- Entacapone
- Foslevodopa with foscarbidopa
- Levodopa with carbidopa and entacapone
- Melatonin
- Opicapone
- Orphenadrine hydrochloride
- Pergolide mesilate
- Pramipexole
- Procyclidine hydrochloride
- Rasagiline mesilate
- Ropinirole hydrochloride
- Rotigotine
- Safinamide
- Selegiline hydrochloride
- Tolcapone
- Trihexyphenidyl hydrochloride
Committee Recommendations (1)
- Levodopa is recommended as a first-line treatment in the early stages of Parkinson's disease where motor symptoms are impacting on quality of life.
- Levodopa may also be a treatment choice in the early stages of Parkinson's disease where motor symptoms do not impact quality of life.
- Levodopa may be considered in the treatment of nocturnal akinesia in Parkinson's disease.
Initiation may be carried out in Primary Care but only after recommendation by a specialist.
Patients in whom Parkinson's is suspected should be referred quickly and untreated to a specialist.